Last $44.09 USD
Change Today -1.59 / -3.48%
Volume 660.7K
LCI On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 4:15 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

lannett co inc (LCI) Snapshot

Open
$45.54
Previous Close
$45.68
Day High
$45.59
Day Low
$43.60
52 Week High
07/3/14 - $51.66
52 Week Low
10/8/13 - $17.00
Market Cap
1.6B
Average Volume 10 Days
661.1K
EPS TTM
$1.49
Shares Outstanding
35.7M
EX-Date
--
P/E TM
29.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for LANNETT CO INC (LCI)

Related News

No related news articles were found.

lannett co inc (LCI) Related Businessweek News

No Related Businessweek News Found

lannett co inc (LCI) Details

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of branded pharmaceutical products in the United States. It offers solid oral, extended release, topical, and oral solution finished dosage forms of drugs that address a range of therapeutic areas. The company provides its products for various medical indications comprising glaucoma, migraine, antibiotic, pain management, anesthetic, endometriosis, anxiety, irritable bowel syndrome, obesity, congestive heart failure, antipsychotic, tuberculosis, thyroid deficiency, dryness of the mouth, epilepsy, gout, low sodium, bronchospasms, hypertension, and gallstone, as well as HIV. It also manufactures active pharmaceutical ingredients. Lannett Company, Inc. markets its products under the Diamox, Fioricet, Fiorinal, Fiorinal w/ Codeine #3, Cleocin, Danocrine, Valium, Bentyl, Tenuate, Dospan, Lanoxin, Adoxa, Periostat, Prolixin, Dilaudid, Niazid, Levoxyl, Synthroid, Loxitane, Adipex-P, Fastin, Salagen, Mysoline, Benemid, Rifadin, Brethine, Dyazide, Actigall, and Retrovir brands. The company sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. It has development and supply agreements with Azad Pharma AG, Swiss Caps of Switzerland, Pharma 2B, the GC Group of Israel, and HEC Pharm Group, as well as with Jerome Stevens Pharmaceuticals, Inc., Cerovene, and Summit Bioscience LLC. The company was founded in 1942 and is based in Philadelphia, Pennsylvania.

399 Employees
Last Reported Date: 08/29/14
Founded in 1942

lannett co inc (LCI) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $539.0K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $317.0K
Chief Operating Officer
Total Annual Compensation: $346.0K
Chief Compliance Officer and Vice President o...
Total Annual Compensation: $230.0K
Chief Information Officer and Vice President ...
Total Annual Compensation: $170.0K
Compensation as of Fiscal Year 2014.

lannett co inc (LCI) Key Developments

United States District Court Dismisses Class Action Lawsuit against Lannett Company, Inc. Without Prejudice

Lannett Company, Inc. announced that the class action lawsuit filed against the company and certain officers in the United States District Court for the Eastern District of Pennsylvania, has been voluntarily dismissed without prejudice by the plaintiff. The complaint alleged that the defendants made a number of false and misleading statements involving pricing of the company's Digoxin product. The dismissal follows the company informing the plaintiff that it had reviewed the complaint and concluded that the claims asserted were without merit, frivolous and subject to sanctions pursuant to the Private Securities Litigation Reform Act and Rule 11 of the Federal Rules of Civil Litigation. The company is reviewing its options to determine whether there is a basis to seek reimbursement of the legal fees and costs incurred defending what it believes was a meritless case.

Lannett Company, Inc. Launches Oxycodone Hydrochloride Oral Solution

Lannett Company, Inc. announced that it has commenced shipping its recently approved Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL. According to IMS, annualized sales of Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL, at average wholesale price (AWP) were approximately $43 million.

Lannett Receives FDA Approval for Oxycodone Hydrochloride Oral Solution USP

Lannett Company, Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL, the therapeutic equivalent to the reference listed drug, Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL, of Lehigh Valley Technologies, Inc. According to IMS, annualized sales of Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL, at Average Wholesale Price (AWP) were approximately $43 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LCI:US $44.09 USD -1.59

LCI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $34.88 USD -1.39
Covisint Corp $4.26 USD +0.11
Pernix Therapeutics Holdings Inc $7.17 USD -0.51
Sagent Pharmaceuticals Inc $31.64 USD +0.54
Vista Pharmaceuticals Ltd 12.00 INR +0.44
View Industry Companies
 

Industry Analysis

LCI

Industry Average

Valuation LCI Industry Range
Price/Earnings 28.2x
Price/Sales 5.9x
Price/Book 5.5x
Price/Cash Flow 28.5x
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LANNETT CO INC, please visit www.lannett.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.